173 related articles for article (PubMed ID: 26088405)
1. Long-term safety and effectiveness of high-dose dimethylfumarate in the treatment of moderate to severe psoriasis: a prospective single-blinded follow-up study.
Lijnen R; Otters E; Balak D; Thio B
J Dermatolog Treat; 2016; 27(1):31-6. PubMed ID: 26088405
[TBL] [Abstract][Full Text] [Related]
2. Dimethyl Fumarate: A Review in Moderate to Severe Plaque Psoriasis.
Blair HA
Drugs; 2018 Jan; 78(1):123-130. PubMed ID: 29236231
[TBL] [Abstract][Full Text] [Related]
3. Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study.
van de Kerkhof PCM; Loewe R; Mrowietz U; Falques M; Pau-Charles I; Szepietowski JC
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):119-126. PubMed ID: 31465585
[TBL] [Abstract][Full Text] [Related]
4. Fumaric acid esters in recalcitrant pediatric psoriasis: A prospective, daily clinical practice case series.
van Geel MJ; van de Kerkhof PC; Oostveen AM; de Jong EM; Seyger MM
J Dermatolog Treat; 2016; 27(3):214-20. PubMed ID: 26452994
[TBL] [Abstract][Full Text] [Related]
5. Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.
Landeck L; Asadullah K; Amasuno A; Pau-Charles I; Mrowietz U
Arch Dermatol Res; 2018 Aug; 310(6):475-483. PubMed ID: 29574575
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus.
Mrowietz U; Barker J; Boehncke WH; Iversen L; Kirby B; Naldi L; Reich K; Tanew A; van de Kerkhof PCM; Warren RB
J Eur Acad Dermatol Venereol; 2018 Oct; 32 Suppl 3():3-14. PubMed ID: 30238510
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm
Mrowietz U; Szepietowski JC; Loewe R; van de Kerkhof P; Lamarca R; Ocker WG; Tebbs VM; Pau-Charles I
Br J Dermatol; 2017 Mar; 176(3):615-623. PubMed ID: 27515097
[TBL] [Abstract][Full Text] [Related]
8. Switch of psoriasis therapy from a fumaric acid ester mixture to dimethyl fumarate monotherapy: Results of a prospective study.
Falkvoll S; Gerdes S; Mrowietz U
J Dtsch Dermatol Ges; 2019 Sep; 17(9):906-912. PubMed ID: 30644638
[TBL] [Abstract][Full Text] [Related]
9. Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.
Dickel H; Bruckner T; Altmeyer P
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1710-1727. PubMed ID: 29705996
[TBL] [Abstract][Full Text] [Related]
10. Fumaric acid esters in the treatment of psoriasis: an Italian experience.
Carboni I; De Felice C; De Simoni I; Soda R; Chimenti S
J Dermatolog Treat; 2004 Jan; 15(1):23-6. PubMed ID: 14754645
[TBL] [Abstract][Full Text] [Related]
11. A safety evaluation of dimethyl fumarate in moderate-to-severe psoriasis.
Reszke R; Szepietowski JC
Expert Opin Drug Saf; 2020 Apr; 19(4):373-380. PubMed ID: 32129112
[No Abstract] [Full Text] [Related]
12. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study.
Mrowietz U; Christophers E; Altmeyer P
Br J Dermatol; 1998 Mar; 138(3):456-60. PubMed ID: 9580799
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of fumaric acid esters in combination with phototherapy in patients with moderate-to-severe plaque psoriasis (FAST).
Weisenseel P; Reich K; Griemberg W; Merten K; Gröschel C; Gomez NN; Taipale K; Bräu B; Zschocke I
J Dtsch Dermatol Ges; 2017 Feb; 15(2):180-186. PubMed ID: 28214304
[TBL] [Abstract][Full Text] [Related]
14. Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis.
Warren RB; Barker JNW; Van de Kerkhof P; Reich K; Mrowietz U
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):e352-e353. PubMed ID: 31033034
[No Abstract] [Full Text] [Related]
15. Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris.
Gollnick H; Altmeyer P; Kaufmann R; Ring J; Christophers E; Pavel S; Ziegler J
Dermatology; 2002; 205(1):46-53. PubMed ID: 12145434
[TBL] [Abstract][Full Text] [Related]
16. Fumaric acid esters for psoriasis: a systematic review.
Smith D
Ir J Med Sci; 2017 Feb; 186(1):161-177. PubMed ID: 27271164
[TBL] [Abstract][Full Text] [Related]
17. Use of fumaric acid esters in psoriasis.
Roll A; Reich K; Boer A
Indian J Dermatol Venereol Leprol; 2007; 73(2):133-7. PubMed ID: 17456929
[TBL] [Abstract][Full Text] [Related]
18. Addition of an oral histamine antagonist to reduce adverse events associated with fumaric acid esters in the treatment of psoriasis: a randomized double-blind placebo-controlled trial.
Balak DM; Fallah-Arani S; Venema CM; Neumann HA; Thio HB
Br J Dermatol; 2015 Mar; 172(3):754-9. PubMed ID: 25041291
[TBL] [Abstract][Full Text] [Related]
19. Controlling the pro-inflammatory function of 6-sulfo LacNAc (slan) dendritic cells with dimethylfumarate.
Oehrl S; Olaru F; Kunze A; Maas M; Pezer S; Schmitz M; Schäkel K
J Dermatol Sci; 2017 Sep; 87(3):278-284. PubMed ID: 28732748
[TBL] [Abstract][Full Text] [Related]
20. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study.
Wain EM; Darling MI; Pleass RD; Barker JN; Smith CH
Br J Dermatol; 2010 Feb; 162(2):427-34. PubMed ID: 19519838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
